The epithelial–mesenchymal plasticity landscape: principles of design and mechanisms of regulation

J Haerinck, S Goossens, G Berx - Nature Reviews Genetics, 2023 - nature.com
Epithelial–mesenchymal plasticity (EMP) enables cells to interconvert between several
states across the epithelial–mesenchymal landscape, thereby acquiring hybrid epithelial …

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Y He, W Xu, YT **
SC Baca, JH Seo, MP Davidsohn, B Fortunato… - Nature medicine, 2023 - nature.com
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical
decisions in cancer care, they have limited ability to identify the transcriptional programs that …

Developmental cell programs are co-opted in inflammatory skin disease

G Reynolds, P Vegh, J Fletcher, EFM Poyner… - Science, 2021 - science.org
INTRODUCTION Human skin provides vital protection from water loss and from external
insult through structural adaptations and interplay with the innate and adaptive immune …

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

MK Bakht, Y Yamada, SY Ku, VB Venkadakrishnan… - Nature cancer, 2023 - nature.com
Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

KL Morel, AV Sheahan, DL Burkhart, SC Baca… - Nature cancer, 2021 - nature.com
Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

J Majidpoor, K Mortezaee - Clinical Immunology, 2021 - Elsevier
Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally
considered as low immune-reactive cancers that represent either limited infiltration of …

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer

SG Zhao, M Bootsma, S Zhou, R Shrestha… - Nature …, 2024 - nature.com
The impact of variations in the three-dimensional structure of the genome has been
recognized, but solid cancer tissue studies are limited. Here, we performed integrated deep …

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer

A Davies, S Nouruzi, D Ganguli, T Namekawa… - Nature cell …, 2021 - nature.com
Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

X Qiu, N Boufaied, T Hallal, A Feit, A de Polo… - Nature …, 2022 - nature.com
Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …